Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNP-MMP-14 + TNP-Cat-B is a combination of two theranostic nanoparticles designed for dual-enzyme activation in cancer therapy. The combination leverages the tumor-targeting and imaging capabilities of each nanoparticle to enhance tumor accumulation and therapeutic efficacy compared to monotherapy with either agent alone. Specifically, TNP-MMP-14 targets matrix metalloproteinase 14 (MMP-14), an enzyme overexpressed in various cancers and associated with tumor progression, invasion, and immune cell infiltration. TNP-Cat-B targets cathepsin B (Cat-B), another protease implicated in cancer metastasis. This dual-enzyme activated approach allows for improved image-guided drug delivery and potentially greater antitumor effects by exploiting the unique proteolytic environment of tumors[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TNP-MMP-14 + TNP-Cat-B.